Skip to main content

Advertisement

SpringerLink
Log in

Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

The optimal antithrombotic treatment for patients on oral anticoagulants (OAC) undergoing percutaneous coronary intervention (PCI) is controversial. We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES).

Methods and results

In this retrospective analysis, all AF patients treated with dual therapy were retrospectively identified. Efficacy endpoints included cardiac death, myocardial infarction (MI), stent thrombosis (ST) and cerebrovascular stroke at follow-up, while safety was assessed by bleeding events defined by the Bleeding Academic Research Consortium (BARC). Between January 2008 and August 2010, 221 patients with high-risk AF received a DES and a dual therapy with OAC and clopidogrel. At a mean follow-up of 19 months, bleeding complications occurred in 22 patients (10 %), more than half of them (n = 12) were related to the index PCI. We observed 11 cardiac deaths (4.9 %), 9 MIs (4.1 %), 3 definite (1.4 %) and no probable ST at follow-up. All definite ST occurred after cessation of clopidogrel at 8, 22, and 30 months after PCI in patients not adequately anticoagulated. Eight patients (3.6 %) had an ischemic stroke, five of which after temporary or permanent cessation of OAC.

Conclusion

The data generated from this large single-center experience in AF patients treated with DES revealed that dual therapy with OAC plus clopidogrel for 6–12 months followed by monotherapy with OAC appears both safe and effective at long-term follow-up. However, after clopidogrel cessation, maintaining therapeutic anticoagulation with an INR >2 is essential to prevent both thrombotic and embolic events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: an anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375

    Article  PubMed  CAS  Google Scholar 

  2. Alexander KP, Galanos AN, Jollis JG, Stafford JA, Peterson ED (2001) Post-myocardial infarction risk stratification in elderly patients. Am Heart J 142:37–42

    Article  PubMed  CAS  Google Scholar 

  3. Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith Sc Jr, Peterson ED, Becker RC (2008) Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 155:361–368

    Article  PubMed  Google Scholar 

  4. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothou BK, Ting HH, ACCF, AHA, SCAI (2011) 2011 ACCF/AHA/SCAI Guideline for perctaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–e122

    Article  PubMed  Google Scholar 

  5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamago JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367

    Article  PubMed  Google Scholar 

  6. Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GY (2008) Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51:818–825

    Article  PubMed  CAS  Google Scholar 

  7. Karjalainen PP, Porela P, Ylitalo A, Vikman K, Vaittinen MA, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28:726–732

    Article  PubMed  CAS  Google Scholar 

  8. Denas G, Padayattil Jose S, Gresele P, Erba N, Testa S, De Micheli V, Quintavalla R, Poli D, Bracco A, Fierro T, Iliceto S, Penga V (2013) Major bleeding in patients undergoing PCI and triple or duale antithrombotic therapy: a parallel-cohort study. J Thromb Thrombolysis 35:178–184

    Article  PubMed  CAS  Google Scholar 

  9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van ES GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351

    Article  PubMed  Google Scholar 

  10. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgmigli M, Vranckx P, Taggert D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747

    Article  PubMed  Google Scholar 

  11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870

    Article  PubMed  CAS  Google Scholar 

  12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272

    Article  PubMed  Google Scholar 

  13. Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werft F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB (2009) Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30:2019–2028

    Article  PubMed  CAS  Google Scholar 

  14. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW (2011) Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZON-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 58:1750–1756

    Article  PubMed  Google Scholar 

  15. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368

    Article  PubMed  Google Scholar 

  16. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marin F, Consesnus Document of European Society of Cardiology Working Group on Thrombosis (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 31:1311–1318

    Article  PubMed  Google Scholar 

  17. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolollo DJ (2011) Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv 4:522–534

    Article  PubMed  Google Scholar 

  18. Airaksinen KE, Suurmunne H, Porela P, Niemelä M, Vikman S, Puurunen M, Annala AP, Biancari F, Karlajainen PP (2010) Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol 106:175–179

    Article  PubMed  Google Scholar 

  19. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S for the ACTIVE Writing Group of the ACTIVE Investigators (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912

    Article  PubMed  CAS  Google Scholar 

  20. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators (2006) Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 152:967–973

    Article  PubMed  CAS  Google Scholar 

  21. Mehilli J Intracoronary stenting and antithrombotic regimen: testing of a six-week versus a six-month clopidogrel treatment regimen in patients with concomitant aspirin and oral anticoagulation therapy following drug-eluting stenting (ISAR-Triple). Clinicaltrials.gov NCT00776633

  22. Sambola A Test of efficacy and safety of the dual antiplatelet therapy compared to the combination of oral anticoagulant therapy + dual antiplatelet therapy in patients with atrial fibrillation with low-moderate risk submitted to coronary stent implantation. Clinicaltrials.gov NCT01141153

  23. Dewilde W, Oirbans T, Verheugt F, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heertermans AA, Vis MM, Tijsen JG, van`t Hof AW, Ten Berg JM, WOEST Study Investigators (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115

    Article  PubMed  CAS  Google Scholar 

  24. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR (2009) Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 157:132–140

    Article  PubMed  Google Scholar 

  25. Loncoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863

    Article  Google Scholar 

  26. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216

    Article  PubMed  CAS  Google Scholar 

  27. Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Schöller R, Zahn R, Diller F, Darius H, Dill T, Huber K (2011) Efficacy and safety of a high loading dose of clopidogrel administration prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312

    Article  PubMed  Google Scholar 

  28. Zahn R, Neumann FJ, Büttner HJ, Richardt G, Schneider S, Levenson B, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Hamm CW (2012) Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clin Res Cardiol 101:709–716

    Article  PubMed  CAS  Google Scholar 

  29. Cuneo A, Bramlage P, Hochadel M, Senges J, Nienaber C, Kuck KH, Tebbe U (2012) Concurrent drug-eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. Clin Res Cardiol 101:281–288

    Article  PubMed  CAS  Google Scholar 

  30. Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA (2013) Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol 102:371–381

    Article  PubMed  CAS  Google Scholar 

  31. Gilard M, Blachard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le Breton H, Bochat J, STENTICO Investigators (2009) Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting [from stenting and oral anticoagulants (STENTICO)]. Am J Cardiol 104:338–342

    Article  PubMed  CAS  Google Scholar 

  32. Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schömig A (2010) Oral anticoagulation with coumarin derivates and antiplatelet effects of clopidogrel. Eur Heart J 31:1205–1211

    Article  PubMed  CAS  Google Scholar 

  33. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themelses E, Varrone J, Wang S, Slings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin LM, RE-LY Steering Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  PubMed  CAS  Google Scholar 

  34. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Senson JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  PubMed  CAS  Google Scholar 

  35. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  PubMed  CAS  Google Scholar 

  36. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators, (2007) Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 357:2001–2015

    Article  PubMed  CAS  Google Scholar 

  37. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Cardiology, Heart Center, Segeberger Kliniken GmbH (Academic Teaching Hospital of the Universities of Kiel and Hamburg), Bad Segeberg, 23795, Hamburg, Germany

    Yazdan Seivani, Mohamed Abdel-Wahab, Volker Geist, Gert Richardt, Dmitriy S. Sulimov, Mohamed El-Mawardy, Ralph Toelg & Ibrahim Akin

Authors
  1. Yazdan Seivani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Abdel-Wahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Geist
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gert Richardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dmitriy S. Sulimov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed El-Mawardy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ralph Toelg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ibrahim Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim Akin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seivani, Y., Abdel-Wahab, M., Geist, V. et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol 102, 799–806 (2013). https://doi.org/10.1007/s00392-013-0592-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-013-0592-z

Keywords

Search

Navigation